Abstract:Chronic hepatitis B (CHB) continues to contribute to worldwide morbidity and mortality significantly. Scientists, clinicians, pharmaceutical companies, and health organizations have dedicated substantial Intellectual and monetary resources to finding a cure, increasing immunization rates, and reducing the global burden of CHB. National and international health-related organizations including the center for disease control, the national institute of health, the American Association for the study of liver disease (AASLD), The European association for the study of the Liver (EASL), The Asia Pacific association for the study of the Liver (APASL) and the world health organization release periodic recommendations for disease prevention and treatment. Our review of the most recent guidelines by EASL, AASLD, APASL, and Taiwan Association for the Study of the Liver revealed that an overwhelming majority of cited studies were published before 2018. We reviewed Hepatitis B-related literature published 2018 onwards to identify recent developments and current barriers that will likely direct future efforts towards eradicating hepatitis B. The breakthrough in our understanding of the hepatitis B virus life cycle and resulting drug development is encouraging with significant room for further progress. Data from high-risk populations, most vulnerable to the devastating effects of hepatitis B infection and reactivation remain sparse. Utilization of systems approach, optimization of experimental models, identification and validation of next-generation biomarkers, and precise modulation of the human immune response will be critical for future innovation. Within the foreseeable future, new treatments will likely complement conventional therapies rather than replace them. Most Importantly, pragmatic management of CHB related population health challenges must be prioritized to produce real-world results.

[Opportunities and Challenges for the Treatment of Chronic Hepatitis C].

[Chronic Hepatitis C: Achievement, Challenge and Strategy to Eliminate As a Public Health Threat].

Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China

Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China

Current Advances in the Elimination of Hepatitis B in China by 2030

Acute Hepatitis C: Current Status and Future Perspectives

Countdown to 2030: Eliminating Hepatitis B Disease, China

Realm of hepatitis E: Challenges and opportunities.

Global importance of new treatment strategies to efforts to control hepatitis B virus

Current challenges and the management of chronic hepatitis C in mainland China.

Comprehensive Approach to Controlling Chronic Hepatitis B in China

"Treat-all" Strategy for Patients with Chronic Hepatitis B Virus Infection in China: Are We There Yet?

Advances in treatment and prevention of hepatitis B

Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies

Present and future management of viral hepatitis

Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives

[Recent Advances in the Treatment of Hepatitis C in 2016].

How would China achieve WHO's target of eliminating HCV by 2030?

Current treatment of chronic hepatitis B: Clinical aspects and future directions

Global Elimination of Hepatitis C Virus

Global control of hepatitis C: where challenge meets opportunity